Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$0.28
C$0.25
C$0.10
C$0.35
C$39.77M2.544,405 shs2,008 shs
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
$10.30
$9.72
$18.20
$450MN/A2.07 million shs40,482 shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
-3.51%0.00%-1.79%+48.65%+10.00%
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
0.00%0.00%0.00%0.00%0.00%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/AN/AN/AN/AN/A
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/A
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$324.55K122.53C$0.01 per share39.00C$0.02 per share14.00
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/A$0.56 per shareN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
-C$7.21M-C$0.21N/AN/AN/A-169.75%-45.14%6/26/2024 (Estimated)
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
-$7.92MN/A0.00N/AN/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest BU, TRIL, and FRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/14/2024Q3 2024
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/A-C$0.02-C$0.02-C$0.02N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/AN/A
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
190.99
1.63
1.71
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
0.37
0.37
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.28%
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
87.15%

Insider Ownership

CompanyInsider Ownership
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
25.66%
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
9.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
24142.03 millionN/ANot Optionable
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A37.50 millionN/ANot Optionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

BU, TRIL, and FRX Headlines

SourceHeadline
Cachet Bicycle shakes off COVIDCachet Bicycle shakes off COVID
baytoday.ca - February 25 at 12:23 PM
Rejuvenate your look with a trip to Fourth Avenue Medical AestheticsRejuvenate your look with a trip to Fourth Avenue Medical Aesthetics
chch.com - January 30 at 5:32 PM
TTI apprehends motorists for illegal removal of clamps, hunt for four others underwayTTI apprehends motorists for illegal removal of clamps, hunt for four others underway
bulawayo24.com - January 30 at 5:32 PM
BridgeBio raises $1.25bn, and other biotech financingsBridgeBio raises $1.25bn, and other biotech financings
pharmaphorum.com - January 19 at 7:18 AM
Ratio Therapeutics Raises $50M in Series B FinancingRatio Therapeutics Raises $50M in Series B Financing
precisionmedicineonline.com - January 17 at 1:39 PM
Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com
businesswire.com - November 10 at 1:22 PM
Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions
benzinga.com - November 8 at 1:30 AM
The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period
uk.finance.yahoo.com - July 31 at 9:03 AM
Ratio Therapeutics unveils new research and development facilityRatio Therapeutics unveils new research and development facility
biopharma-reporter.com - May 15 at 10:33 AM
WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: Can Cause Even DeathWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'
msn.com - April 26 at 12:18 AM
Leukemia Therapeutics Global Market Report 2023Leukemia Therapeutics Global Market Report 2023
uk.finance.yahoo.com - April 4 at 10:35 AM
Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
finance.yahoo.com - March 28 at 9:12 AM
Trillium House, an affordable housing project in Warrenton, close to completionTrillium House, an affordable housing project in Warrenton, close to completion
dailyastorian.com - January 10 at 12:26 AM
FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular CarcinomaFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma
nz.finance.yahoo.com - October 19 at 9:39 AM
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
seekingalpha.com - September 14 at 9:48 AM
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of DirectorsZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
nz.finance.yahoo.com - September 12 at 7:55 AM
Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is NeededPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed
seekingalpha.com - August 17 at 11:07 AM
TTI reviews parking modelTTI reviews parking model
chronicle.co.zw - August 10 at 10:41 PM
TTI working round the clock to configure its systemsTTI working round the clock to configure its systems
chronicle.co.zw - August 10 at 10:41 PM
Pfizer in advanced talks to buy firm making sickle cell drugsPfizer in advanced talks to buy firm making sickle cell drugs
pmnewsnigeria.com - August 7 at 3:57 AM
10 Psychedelics CEOs To Pay Attention To In 202210 Psychedelics CEOs To Pay Attention To In 2022
markets.businessinsider.com - June 22 at 10:08 AM
Highlights from ASCO Annual Meeting 2022Highlights from ASCO Annual Meeting 2022
healio.com - June 15 at 1:37 PM
Chlormethine gel may be more effective than ointment for mycosis fungoidesChlormethine gel may be more effective than ointment for mycosis fungoides
healio.com - May 27 at 4:34 PM
Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?
edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Burcon NutraScience logo

Burcon NutraScience

TSE:BU
Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company offers Peazazz and Peazac, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS, a blend of Peazazz pea protein and Supertein canola protein; Nutratein-TZ, a blend of Peazac pea protein and Puratein canola protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and non-beverage plant-based products. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.
Forest Road Acquisition logo

Forest Road Acquisition

NYSE:FRX
Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.
Trillium Therapeutics logo

Trillium Therapeutics

NASDAQ:TRIL
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.